BioWorld MedTech

Jan. 11, 2016

Diabetic Foot Ulcer Market: Omnigraft approval seen as catalyst for Integra, DFU market

A new FDA approval is expected to be an important catalyst for Integra Lifesciences Corp. (Plainsboro, N.J.) and represents a step in the right direction for the broader diabetic foot ulcer (DFU) market. Read More

Inside the Beltway: Hatch, Wyden urge CMS to redo PAMA reporting mandates

Call Me Maybe: Cardiac variants fail to predict risk in prospective study

TAVR provides fertile market for firm: Vivasure Medical picks up CE mark for percutaneous vascular closure device

MDD's Company Stock Report

Opponents say not a wise move: Indian government urged to rethink health care price caps

Daily M&A: S&N completes acquisition of Blue Belt Holdings for $275M

Patent Watch: Biomarker Strategies gains key patents for core technology

Products

People in Places

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 27, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...